Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MethylGene has initiated a Phase II clinical trial evaluating MGCD0103, an isoform-selective histone deacetylase inhibitor product candidate, in combination with Vidaza, a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia.
Subscribe to our email newsletter
The study is a three-arm, randomized trial which will enroll up to 180 patients at cancer centers in North America and Europe.
Charles Craddock, professor of haemato-oncology at University of Birmingham, UK, said: “Vidaza recently demonstrated a major survival benefit when used to treat patients with high-risk myelodysplastic syndromes (MDS).
“The Phase I/II data with this combination were also compelling, and we aim to determine definitively whether combination treatment is superior to monotherapy in MDS and acute myeloid leukemia.”